JNJ-10198409
Based on 1 publication(s) in Google Scholar
JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC50=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.58%
- CAS 番号: 627518-40-5
- 分子式: C18H16FN3O2
- 分子量:325.34
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Angiogenesis-Related Compound Library
HY-L088
-
Targeted Diversity Library
HY-L099
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Cytokine Inhibitors Library
HY-L161
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
MedChemExpress（MCE）の使用を引用している文献 JNJ-10198409
More
生物活性
|
PDGFRβ 4.2 nM (IC50) |
PDGFRα 45 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
0.007 μM
Compound: 17, JNJ-10198409
|
Antiproliferative activity against human melanoma tumor cell line A375
Antiproliferative activity against human melanoma tumor cell line A375
|
[PMID: 16366598] |
| ASPC1 | IC50 |
0.592 μM
Compound: 17, JNJ-10198409
|
Antiproliferative activity against human pancreatic tumor cell line AsPC1
Antiproliferative activity against human pancreatic tumor cell line AsPC1
|
[PMID: 16366598] |
| HUVEC | IC50 |
4.87 μM
Compound: 17, JNJ-10198409
|
Antiproliferative activity against LSGS stimulated HUVEC
Antiproliferative activity against LSGS stimulated HUVEC
|
[PMID: 16366598] |
| LNCaP | IC50 |
0.009 μM
Compound: 17, JNJ-10198409
|
Antiproliferative activity against human prostate tumor cell line LnCAP
Antiproliferative activity against human prostate tumor cell line LnCAP
|
[PMID: 16366598] |
| LoVo | IC50 |
0.017 μM
Compound: 17, JNJ-10198409
|
Antiproliferative activity against human colon tumor cell line LoVo
Antiproliferative activity against human colon tumor cell line LoVo
|
[PMID: 16366598] |
| NCI-H460 | IC50 |
0.01 μM
Compound: 17, JNJ-10198409
|
Antiproliferative activity against human lung tumor cell line H460
Antiproliferative activity against human lung tumor cell line H460
|
[PMID: 16366598] |
| PC-3 | IC50 |
0.027 μM
Compound: 17, JNJ-10198409
|
Antiproliferative activity against human prostate tumor cell line PC3
Antiproliferative activity against human prostate tumor cell line PC3
|
[PMID: 16366598] |
| T47D | IC50 |
0.032 μM
Compound: 17, JNJ-10198409
|
Antiproliferative activity against human breast tumor cell line T47D
Antiproliferative activity against human breast tumor cell line T47D
|
[PMID: 16366598] |
| U-87MG ATCC | IC50 |
13 μM
Compound: 17, JNJ-10198409
|
Antiproliferative activity against human glioma tumor cell line U87MG
Antiproliferative activity against human glioma tumor cell line U87MG
|
[PMID: 16366598] |
化学情報
-
CAS 番号 627518-40-5
-
性状 Solid
-
分子量 325.34
-
分子式 C18H16FN3O2
-
Color Light yellow to yellow
-
SMILES
COC1=CC2=C(C=C1OC)CC3=C2NN=C3NC4=CC=CC(F)=C4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Stem Cells Int
Endothelial Cells Promote Migration of Mesenchymal Stem Cells via PDGF-BB/PDGFR β-Src-Akt in the Context of Inflammatory Microenvironment upon Bone Defect. [Abstract]2022 Sep 24:2022:2401693. PMID: 36193255
溶剤 & 溶解度
DMSO : 83.33 mg/mL (256.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug;4(8):1198-204. [Content Brief]
[2]. Ho CY, et al. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem. 2005 Dec 29;48(26):8163-73. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0737 mL | 15.3685 mL | 30.7371 mL | 76.8427 mL |
| 5 mM | 0.6147 mL | 3.0737 mL | 6.1474 mL | 15.3685 mL | |
| 10 mM | 0.3074 mL | 1.5369 mL | 3.0737 mL | 7.6843 mL | |
| 15 mM | 0.2049 mL | 1.0246 mL | 2.0491 mL | 5.1228 mL | |
| 20 mM | 0.1537 mL | 0.7684 mL | 1.5369 mL | 3.8421 mL | |
| 25 mM | 0.1229 mL | 0.6147 mL | 1.2295 mL | 3.0737 mL | |
| 30 mM | 0.1025 mL | 0.5123 mL | 1.0246 mL | 2.5614 mL | |
| 40 mM | 0.0768 mL | 0.3842 mL | 0.7684 mL | 1.9211 mL | |
| 50 mM | 0.0615 mL | 0.3074 mL | 0.6147 mL | 1.5369 mL | |
| 60 mM | 0.0512 mL | 0.2561 mL | 0.5123 mL | 1.2807 mL | |
| 80 mM | 0.0384 mL | 0.1921 mL | 0.3842 mL | 0.9605 mL | |
| 100 mM | 0.0307 mL | 0.1537 mL | 0.3074 mL | 0.7684 mL |
Powered by Bioz